Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2019 Apr 6

PMID 30949507

Citations 6

Authors

Jianping Wu

Qianxia Wu

Minyi Wu

Weilin Mao

Affiliations

Soon will be listed here.

Abstract

Background: Some studies have reported that renal dysfunction is associated with poor prognosis in cirrhotic patients. Serum cystatin C (CysC) is an accurate biomarker for early renal dysfunction. This study aimed to assess the prognostic value of serum CysC levels in patients with hepatitis B virus-related decompensated cirrhosis (HBV-DeCi).

Methods: This retrospective study included 75 subjects who had been diagnosed with HBV-DeCi. The association between serum CysC and prognosis was estimated by receiver operating characteristic curve analysis and a multivariable logistic regression model.

Results: Serum CysC levels were higher in nonsurvivors than in survivors and were positively correlated with model for end-stage liver disease (MELD) scores. In multivariate analysis, CysC and the MELD score were independent prognostic factors in all HBV-DeCi patients. However, only serum CysC was an independent factor predicting mortality in patients with normal creatinine levels.

Conclusions: These data suggest that high serum CysC levels can be considered an independent biomarker of 3-month mortality in patients with HBV-DeCi.

Citing Articles

Association of Cystatin C Level with All-cause Mortality in Patients with Liver Cirrhosis: A Meta-analysis.

Wang X, Xu W, Yao L, Jie Y, Gao Z, Fan Y Curr Med Chem. 2024; 31(25):3977-3986.

PMID: 38173071 DOI: 10.2174/0109298673247263231123114043.

Platelet-to-Monocyte Ratio as a Novel Promising Agent for the Prognosis of Hepatitis B Virus-Associated Decompensated Cirrhosis.

Zhou J, Li X, Wang M, Gu C, Liu J Can J Gastroenterol Hepatol. 2023; 2023:6646156.

PMID: 37485072 PMC: 10361825. DOI: 10.1155/2023/6646156.

Serum Cystatin C Levels Are Associated With Obesity in Adolescents Aged 14-17 Years.

Huo Y, Wei W, Liu Y, Ma Y, Tao J, Wang N Front Endocrinol (Lausanne). 2022; 13:816201.

PMID: 35185798 PMC: 8854751. DOI: 10.3389/fendo.2022.816201.

Association of Low High-Density Lipoprotein Cholesterol Levels with Poor Outcomes in Hepatitis B-Associated Decompensated Cirrhosis Patients.

He X, Liu X, Peng S, Han Z, Shen J, Cai M Biomed Res Int. 2021; 2021:9927330.

PMID: 34355041 PMC: 8331308. DOI: 10.1155/2021/9927330.

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases.

Wu J, Mao W Dis Markers. 2020; 2020:2471252.

PMID: 32774512 PMC: 7391085. DOI: 10.1155/2020/2471252.

References

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura P . A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001; 34(1):46-52. DOI: 10.1016/s0168-8278(00)00011-8. View

Nair S, Verma S, Thuluvath P . Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002; 35(5):1179-85. DOI: 10.1053/jhep.2002.33160. View

Fontana R, Hann H, Perrillo R, Vierling J, Wright T, Rakela J . Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002; 123(3):719-27. DOI: 10.1053/gast.2002.35352. View

Freeman Jr R, Wiesner R, Harper A, McDiarmid S, Lake J, Edwards E . The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002; 8(9):851-8. DOI: 10.1053/jlts.2002.35927. View

Longheval G, Vereerstraeten P, Thiry P, Delhaye M, Le Moine O, Deviere J . Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. Liver Transpl. 2003; 9(3):260-7. DOI: 10.1053/jlts.2003.50049. View

Bellomo R, Kellum J, Ronco C . Defining acute renal failure: physiological principles. Intensive Care Med. 2003; 30(1):33-7. DOI: 10.1007/s00134-003-2078-3. View

Durand F, Valla D . Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005; 42 Suppl(1):S100-7. DOI: 10.1016/j.jhep.2004.11.015. View

Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D . Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther. 2007; 26(7):969-78. DOI: 10.1111/j.1365-2036.2007.03443.x. View

10.

Seo Y, Jung E, An H, Kim J, Jung Y, Kim J . Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int. 2009; 29(10):1521-7. DOI: 10.1111/j.1478-3231.2009.02105.x. View

11.

Mao W, Ye B, Lin S, Fu Y, Chen Y, Chen Y . Prediction value of model for end-stage liver disease scoring system on prognosis in the acute on chronic liver failure patients with plasma exchange treatment. ASAIO J. 2010; 56(5):475-8. DOI: 10.1097/MAT.0b013e3181e6bf13. View

12.

Sharawey M, Shawky E, Ali L, Mohammed A, Hassan H, Fouad Y . Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int. 2011; 5(4):927-33. DOI: 10.1007/s12072-011-9266-y. View

13.

Wang S, Wang J, Chen J, Giri R, Chen M . Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients. Chin Med J (Engl). 2012; 125(12):2157-62. View

14.

Wan Z, Wang J, You S, Liu H, Zhu B, Zang H . Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2014; 19(48):9432-8. PMC: 3882419. DOI: 10.3748/wjg.v19.i48.9432. View

15.

Moller S, Krag A, Bendtsen F . Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int. 2014; 34(8):1153-63. DOI: 10.1111/liv.12549. View

16.

. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 385(9963):117-71. PMC: 4340604. DOI: 10.1016/S0140-6736(14)61682-2. View

17.

Wan Z, Wu Y, Yi J, You S, Liu H, Sun Z . Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure. PLoS One. 2015; 10(1):e0116968. PMC: 4309543. DOI: 10.1371/journal.pone.0116968. View

18.

Harrison P . Management of patients with decompensated cirrhosis. Clin Med (Lond). 2015; 15(2):201-3. PMC: 4953743. DOI: 10.7861/clinmedicine.15-2-201. View

19.

Uguen T, Jezequel C, Ropert M, Houssel-Debry P, Latournerie M, Laine F . Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation. Liver Int. 2015; 36(4):547-54. DOI: 10.1111/liv.12989. View

20.

Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M . Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017; 66(4):1232-1241. DOI: 10.1002/hep.29290. View